Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) has shared an announcement.
Hansa Biopharma and Genethon have announced successful results from a clinical trial using imlifidase as a pretreatment for gene therapy in a patient with Crigler-Najjar syndrome who is immune to AAV vectors. This breakthrough could potentially expand gene therapy options for patients previously ineligible due to immunity, marking a significant advancement in the treatment of rare genetic diseases.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma is a Sweden-based leader in IgG cleaving enzyme technology, focusing on developing treatments for rare diseases. Their primary product, imlifidase, is an enzyme that temporarily inhibits immune responses, and is approved for use in kidney transplant patients in several countries.
Average Trading Volume: 598,595
Technical Sentiment Signal: Buy
Current Market Cap: SEK4.09B
For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.